Detalhe da pesquisa
1.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Clin Infect Dis
; 78(4): 870-879, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967326
2.
Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast.
Malar J
; 15: 213, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27075879
3.
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
Vaccine
; 38(4): 897-906, 2020 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31708182
4.
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Hum Vaccin Immunother
; 15(10): 2386-2398, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31012786
5.
Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study.
PLoS One
; 12(5): e0177382, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28493930